Ambulance steroid shot may cut heart attack deaths, large trial underway

NCT ID NCT07478003

Recruiting now Disease control Sponsor: Thomas Engstrom Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a single high dose of the steroid methylprednisolone, given in the ambulance before opening the blocked artery, can reduce deaths in people having a major heart attack (STEMI). About 5,200 adults will be randomly assigned to receive either the steroid or a placebo during transport. The main goal is to see if the treatment lowers the risk of dying from any cause over the following years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methylprednisolone (a steroid drug)
What this could lead to: If it works, this could become a standard prehospital treatment to reduce deaths and heart failure after a major heart attack.
What could go wrong: This is a large phase 3 trial, but earlier phase 2 results only showed trends, not proof. Steroids have risks like infection and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STEMI - ST ELEVATION MYOCARDIAL INFARCTION

Contacts and locations

Locations

Aalborg University Hospital
NOT_YET_RECRUITING

Aalborg, Denmark
Odense University Hospital
NOT_YET_RECRUITING

Odense, Denmark
Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark
Skejby, Aarhus University Hospital
NOT_YET_RECRUITING

Aarhus, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.